At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 132 enrolled
Drug / intervention
trabectedindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult
European Organisation for Research and Treatment of Cancer - EORTC·interventional·Posted Jun 3, 2004·Updated Sep 24, 2012
In Brief
A Phase 2 clinical trial evaluating trabectedin for Brain and Central Nervous System Tumors and 5 related conditions. Completed, enrolled 132 participants.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have advanced soft tissue sarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrain and Central Nervous System Tumors, Endometrial Cancer, Gastrointestinal Stromal Tumor, Ovarian Cancer, Sarcoma, Small Intestine Cancer
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Primary CompletionNov 2000
First PostedJun 2004
TodayJul 2026
First PostedJun 3, 2004
Primary CompletionNov 1, 2000
TodayJul 2, 2026
Posted 22.1 years ago
Interventions
trabectedindrug